ArticleBMC pulmonary medicine2022

STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life.

Jan A Witte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.